Rationale: Both nuclear factors of activated T cells (NFAT) and nuclear factor-B (NFB) are Rel homology domain (RHD)-containing transcription factors whose independent activities are critically involved in regulating cardiac hypertrophy and failure.
C ardiac hypertrophy is typically characterized by enlargement of the heart and an increase in myocyte cell volume that occurs in response to hemodynamic stress, acute myocardial injury, infection, or mutations in genes encoding sarcomeric proteins. 1 Pathological hypertrophy of the myocardium temporarily preserves pump function, although prolongation of this state is a leading predictor for the development of arrhythmias and sudden death, as well as dilated cardiomyopathy and heart failure. 2 Neural, humoral, and intrinsic hypertrophic stimuli directly activate membrane-bound receptors that in turn activate nodal intracellular signal transduction pathways such as the mitogen-activated protein kinase (MAPK) cascade, calcineurin-NFAT (nuclear factor of activated T cells), insulin-like growth factor-I-phosphatidylinositol 3-ki-nase-Akt/protein kinase B, and many others. 3 These intracellular signaling cascades then modulate transcriptional regulatory proteins, altering gene expression to facilitate the growth of the heart. For example, transcription factors such as NFAT, myocyte enhancer factor-2 (MEF-2), and GATA4/6 are directly activated by cytoplasmic signaling effectors, which in turn mediate hypertrophic gene expression in cardiomyocytes. 3, 4 Similarly, the transcription factor nuclear factor-(NF)B has been implicated as a key regulator of cardiomyocyte hypertrophy both in vitro and in vivo. 5 However, the integration among these transcriptional effector pathways in the regulation of hypertrophic programming has not been explored in the heart.
The NFB/Rel family of transcription factors participates in the regulation of disparate cellular processes such as proliferation, differentiation, immune responses, cell growth, cardiac hypertrophy, and apoptosis. 6, 7 The Rel family proteins include p65 (RelA), p105/p50, p100/p52, RelB, c-Rel, and the viral oncoprotein v-Rel. All Rel family members are conserved throughout evolution and share a Rel homology domain (RHD) at their N terminus, which mediates DNA binding and protein-protein interaction between family members. These proteins associate as homodimers or heterodimers to form transcriptional regulatory complexes. In unstimulated cells, NFB binds to cytosolic inhibitory proteins, IBs, mediating cytoplasmic retention. On various types of stimulation, IBs are phosphorylated by IB kinase (IKK), causing their degradation and subsequent release of NFB for nuclear translocation. 8, 9 The IKK complex is composed of 2 catalytic subunits (IKK␣ and IKK␤) and a regulatory subunit (IKK␥ or NEMO). Recent data also suggest that NFB can shuttle into the nucleus in nonstimulated cells, although the physiological significance of this finding is unknown. 5 Posttranslational modifications (eg, phosphorylation and acetylation) and physical interaction with coactivators and corepressors have been identified as additional regulatory mechanisms. 10 NFAT transcription factors are also part of the Rel family, where they bear structural similarity to NFB and even bind related or overlapping DNA sequence elements. 6 NFAT transcription factors consist of 5 family members (NFATc1, NFATc2, NFATc3, NFATc4, and NFAT5 [TonEBP]). NFAT transcription factors are normally hyperphosphorylated and sequestered in the cytoplasm but rapidly translocate to the nucleus after calcineurin-mediated dephosphorylation. 11 Genetic and pharmacological studies have shown that the calcineurin-NFAT pathway is both sufficient and necessary for the cardiac hypertrophic response in a number of rodent models. 12, 13 Unlike canonical Rel-containing factors, which often homodimerize on target promoters, NFAT factors share an imperfect RHD that is only capable of weak DNA binding in the monomeric or dimeric state. To strengthen NFAT-DNA interactions, these factors tend to interact with other transcription factors such as AP-1 (c-Jun/c-Fos), GATA-4, and MEF-2. 14 Here, we determined that NFAT and NFB family members could interact and assemble "higher-order" transcriptional complexes that synergistically activate hypertrophic gene expression in the heart.
Methods
An expanded Methods section is available in the online Data Supplement.
Animal Models and Procedures
The generation of RelA (p65) loxP-targeted (fl) mice, in which exons 7 and 10 were flanked by loxP sites, was previously described. 15 Mice harboring the p65fl/fl alleles were crossed with mice expressing Cre recombinase under control of the endogenous Nkx2.5 locus. 16 The NFAT-luciferase reporter transgenic mouse as described previously 17 was crossed with a p65fl/fl Nkx2.5-Cre mouse. All experiments involving animals were approved by the Institutional Animal Care and Use Committees at Cincinnati Children's Hospital Medical Center and University of Washington.
Eight-week-old mice were subjected to transverse aortic constriction (TAC) under isoflurane anesthesia as previously described. 18 Pressure gradients (mm Hg) were calculated from the peak blood velocity (Vmax) (m/s) (PGϭ4ϫVmax 2 ) measured by Doppler across the aortic constriction, which was equivalent in all groups of TAC stimulated mice. All mice were anesthetized with 2% isoflurane by inhalation. Echocardiography was performed in M-mode, using a Hewlett Packard SONOS 5500 instrument equipped with a 15-MHz transducer as described previously. 19 
Luciferase Reporter Assays in Mouse Hearts
In brief, hearts were removed from NFAT-luciferase transgenic mice, some of which were crossed into the p65fl/fl Nkx2.5-Cre background. Hearts were homogenized in 1 mL of luciferase assay buffer (100 mmol/L KH 2 PO4, pH 7.8, 0.5% Nonidet P-40, and 1 mmol/L DTT). Homogenates were centrifuged at 3000g for 10 minutes at 4°C, and the supernatants assayed for luciferase activity as described previously. 17
Cell Culture, Adenoviral Infection, and Immunocytochemistry
Primary neonatal rat cardiomyocytes were prepared from hearts of 1to 2-day-old Sprague-Dawley rat pups as previously described. 20 After separation from fibroblasts, enriched cardiomyocytes were plated on gelatin-coated, 12-well plates for luciferase assays or on 6-cm-diameter dishes for all other experiments. Cells were grown in M199 medium containing 100 U of penicillin-streptomycin/mL and 2 mmol/L L-glutamine without serum for 24 hours before infection. p65 ϩ/ϩ and p65 Ϫ/Ϫ MEFs were kindly provided by David Baltimore (California Institute of Technology). Adenoviral infections were performed as previously described at a multiplicity of infection of 10 -50 plaque-forming units/mL. 21 Cultures were harvested 24 hours after infection, and luciferase assays were preformed as described previously. 21 Ad␤gal, Ad⌬CnA, Adcain, AdNFAT-luciferase reporter, AdNFATc1-GFP (green fluorescent protein), and AdNFATc3-GFP have been previously described. 17, [22] [23] [24] AdNFBluciferase reporter was obtained from Vector Biolabs (Philadelphia, PA). Ad-p65 and Ad-p65-RHD-Myc were a gift of Josef Anrather and Hans Winkler (Harvard University). Adenoviral infections were performed as described previously at a multiplicity of infection of 10 -100 plaque-forming units/mL. 21 Cardiomyocytes were prepared for immunocytochemistry as described previously. 24 Immunocytochemistry was performed using anti-p65 antibody (Santa Cruz Biotechnology), followed by ALEXA Fluor 568 anti-rabbit secondary antibody (Molecular probes). Cells infected with AdNFATc1-GFP or AdNFATc1-SA-GFP were directly visualized by fluorescent microscopy for GFP.
Western Blotting and Gel Shift Assays
Protein extraction from mouse heart or cultured cardiomyocytes and subsequent Western blotting followed by enhanced chemiluminescence detection were performed as previously described. 17, 18 Anti- Myc and anti-GFP antibodies were obtained from Cell Signaling Biotechnology (Beverly, MA). Anti-NFATc1, anti-p65, anti-p105/ p50, and anti-glyceraldehyde-3-phosphate dehydrogenase antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Gel shift assays were performed as previously described. 12, 25 Briefly, 20 g of protein extracts from neonatal cardiomyocytes were incubated in gel shift buffer (12 mmol/L HEPES, pH 7.9, 4 mmol/L Tris, pH 7.9, 50 mmol/L KCl, 12% glycerol, 1.2 mmol/L EDTA, 1 mmol/L DTT, 0.2 mmol/L PMSF, 2 g/mL aprotinin, 2 g/mL leupeptin, 0.7 g/mL pepstatin) with 0.5 g poly (dI-dC) and 32 P-labeled NFAT or NFB consensus DNA sequences for 20 minutes at room temperature. For supershift reactions, 1 L of anti-NFATc1 or anti-p65 antibody was added after 20 minutes of binding reaction. DNA complexes were separated on a 5% nondenaturing polyacrylamide gel in Tris-borate EDTA buffer.
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Immunoprecipitation
Neonatal rat cardiomyocytes were infected with or without specific adenoviruses for 24 hours. Cells were lysed at 4°C in buffer (50 mmol/L Tris-HCl [pH 7.5], 150 mmol/L NaCl, 0.5% Triton X-100) containing protease inhibitors (1 mmol/L phenylmethylsulfonyl fluoride, 1 g/mL leupeptin, 1 g/mL pepstatin, and 1 g/mL aprotinin). Immunoprecipitation was performed as described previously. 21 Whole-cell lysates were cleared by centrifugation at 18 000g for 10 minutes and then incubated with the indicated antibodies and protein A-sepharose beads overnight at 4°C. The beads were washed extensively with binding buffer, and the proteins were resolved on an 8 -12% SDS-PAGE for subsequent Western blotting.
Statistics
All results are presented as meanϮSEM. Paired data were evaluated by Student t test. A 1-way ANOVA with the Bonferroni post hoc test or repeated-measures ANOVA was used for multiple comparisons. PϽ0.05 was considered statistically significant.
Results
Cross-Talk Between NFAT and NFB in Cardiomyocytes
Both calcineurin-NFAT and IKK-NFB signaling pathways have been implicated as critical regulators of cardiomyocyte hypertrophy. 12, 26 We tested the hypothesis that these two previously deemed independent signaling pathways may actually cross-talk with one another. We first examined if NFB can influence NFAT transcriptional activity in cultured neonatal cardiomyocytes infected with adenoviruses encoding an NFAT-dependent luciferase reporter cassette. Indeed, NFAT luciferase activity was stimulated by the hypertrophic agonists phenylephrine, serum, and angiotensin II, but this activation was markedly reduced by inhibition of NFB signaling with the NFB supersuppressor IB␣M, or dominant negative IKK␤ ( Figure 1A) . Similarly, inhibition of NFAT signaling with Cain or Rcan1 diminished hypertrophic agonist-induced NFB luciferase activity ( Figure 1B ). Similar reciprocal regulatory effects between NFAT and NFB were observed in cardiomyocytes treated with tumor necrosis factor-␣ (TNF␣), a cytokine known to activate NFB signaling (Online Figure I, A and B ). Activated calcineurin (⌬CnA)-induced NFAT activity was also significantly re- duced in NFB-p65 null MEFs compared with wild-type MEFs, whereas adenoviral-mediated expression of p65 restored NFAT luciferase activity in p65 null MEFs ( Figure  1C ). Conversely, NFB luciferase activity induced by adenoviral overexpression of IKK␤ or p65 was also largely blocked in calcineurin-deficient MEFs (lacking CnB1 protein). In addition, calcineurin-deficient MEFs showed lower baseline NFB activity compared with wild-type MEFs, suggesting that calcineurin regulates NFB equilibrium even without stimulation ( Figure 1D ). Inhibition of NFB signaling with IB␣M or dnIKK␤ also partially blocked ⌬CnA-induced NFAT luciferase activity, whereas inhibition of NFAT signaling with Cain diminished p65-or IKK␤-induced NFB luciferase activity in cardiomyocytes (Online Figure I, C and D). Consistent with these observations, overexpression of NFATc1 or p65 each cross-stimulated NFB and NFATluciferase activity in cardiomyocytes, whereas coexpression of NFAT with p65 synergistically activated both NFAT and NFB reporter activity ( Figure 1E and 1F). To rule out the involvement of autocrine factors in the observed effects, cardiomyocytes were treated with cultured media collected from cells infected with adenovirus encoding NFAT, p65, or both, or with IKK␤ and other inhibitory viruses for NFAT or NFB signaling (Online Figure I, E , F, and G). No significant changes in NFAT-or NFB-luciferase activity was detected under these conditions, thus excluding a role for secreted autocine factors in potentiating NFAT and NFB transcriptional activation.
Physical Interaction Between NFAT and NFB
Whereas a direct interaction between NFB and NFAT transcription factors has not been demonstrated in cardiomyocytes, a physical association between NFATc1 and c-Rel was previously reported in lymphocytes. 27 Hence, we examined if NFAT interacts with p65-NFB in cardiomyocytes by immunoprecipitation. The results showed that NFATc1 immunoprecipitated with a p65 antibody but not with a nonspecific IgG antibody (Figure 2A ). Conversely, immunoprecipitation of NFATc1 with a GFP antibody resulted in the isolation of p65, suggesting an association between these two transcription factors in cardiomyocytes ( Figure 2B ). Immunoprecipitation experiments were also performed in neonatal cardiomyocytes stimulated with phenylephrine, TNF␣, or vehicle control. Although the interaction between NFAT-p65 was still observed with these agonists, no changes in intensity were observed (Online Figure II) . Because both NFAT and NFB contain a Rel homology domain (RHD), which is important for protein-protein interaction and dimerization, cardiomyocytes infected with an adenovirus encoding p65-RHD showed coimmunoprecipitation with NFATc1 ( Figure  2C ). Importantly, overexpression of p65-RHD disrupted the association between NFATc1 and endogenous p65 ( Figure  2C , middle panel). Overexpression of p65-RHD also partially inhibited calcineurin-induced NFAT luciferase activity, suggesting that p65-RHD acts as dominant negative for endogenous p65 because it lacks a transcriptional activation domain ( Figure 2D ). Full-length p65 localized primarily in the cytoplasm of unstimulated neonatal cardiomyocytes, similar to NFATc1-GFP ( Figure 2E ). However, p65-RHD exclu-sively localized to the nucleus in cultured cardiomyocytes, given its lack of N-and C-terminal regulatory domains, which remarkably induced constitutive nuclear localization of NFATc1-GFP, presumably due to the strong interaction between these proteins ( Figure 2E ). Thus, p65-RHD is sufficient to retain NFATc1 in the nucleus through their interaction.
A gel shift assay was performed with cardiomyocyte protein extracts to determine if NFAT and p65 can form transcriptional complexes. The data show that NFAT DNA-binding activity from this nuclear extract is shifted with an anti-NFAT antibody, as expected, whereas a p65 antibody partially disrupts the NFAT binding complex ( Figure 2F ). Conversely, NFB DNA-binding activity is completely disrupted with the anti-p65 antibody, as expected, whereas the anti-NFAT antibody disrupted and supershifted of the NFB DNA-binding activity ( Figure 2F ). These results indicate that NFB and NFAT are complexed together in cardiomyocyte nuclear extract at baseline.
NFAT and NFB Regulate One Another's Subcellular Shuttling
NFAT activity is typically regulated by calcineurin-mediated dephosphorylation within the cytoplasm, resulting in nuclear translocation and the activation of NFAT responsive genes. Similarly, nuclear translocation of NFB is required for NFB transcriptional activation. We further investigated if NFAT and NFB could potentially regulate one another's subcellular shuttling through their ability to complex together. Cardiomyocytes were infected with an adenovirus encoding NFATc1-GFP or the NFATc1 serine/alanine mutant (NFATc1-SA) that is constitutively nuclear (also fused to GFP). In control cells, both NFATc1 and p65 are primarily localized in the cytoplasm ( Figure 3A and 3B and data not shown). Ionomycin, which activates calcineurin, triggered a robust translocation of NFATc1 to the nucleus ( Figure 3A and 3B). Remarkably, near complete nuclear colocalization of p65 was induced by ionomycin, which is not known to activate NFB directly, suggesting it may be due to NFAT translocation ( Figure 3A and 3B ). In addition, the G-proteincoupled receptor (GPCR) agonist phenylephrine induced both NFATc1 and p65 nuclear translocation in cardiomyocytes ( Figure 3A and 3B) . Importantly, cells infected with a constitutively nuclear NFAT mutant, NFATc1-SA, also showed complete translocation of NFB, whereas uninfected cells in the same dish showed cytoplasmic NFB ( Figure 3A and 3B; arrowheads versus asterisks). These data suggest that NFAT nuclear shuttling is sufficient to produce NFB nuclear translocation in cardiomyocytes.
We also investigated the reciprocal relationship by examining whether activation of NFB could influence NFAT subcellular localization. Coinfection of AdNFATc1-GFP with an adenovirus expressing IKK␤ resulted in robust NFATc1 nuclear translocation ( Figure 3C and 3D) . Similarly, cells overexpressing the constitutively nuclear p65-RHD truncation showed complete translocation of NFATc1-GFP ( Figure 3C and 3D) . Moreover, TNF␣, a known activator of NFB, also induced NFATc1 nuclear translocation in cardiomyocytes. Interestingly, overexpression of the calcineurin inhibitory protein Cain blocked NFATc1 nuclear transloca-tion induced by IKK␤, p65-RHD, or TNF␣ suggesting that basal calcineurin activity is still required for IKK␤ or p65-RHD-induced NFAT nuclear shuttling ( Figure 3C and 3D). Consistent with these observations, IKK␤-induced NFAT-luciferase activity was blocked by inhibition of calcineurin with Cain or Rcan1 ( Figure 3E and 3F) . Importantly, inhibition of NFB with the IB␣M mutant abrogated IKK␤induced NFAT activity, suggesting an NFB-dependent action for IKK␤ in regulating NFAT.
Ablation of p65 Diminishes NFAT Transcriptional Activity in the Heart
p65 is one of the major NFB subunits expressed in the myocardium. We determined that p65 protein expression is increased in pressure overload-induced hypertrophic hearts in the mouse, with no significant change in p50 expression, another prominent NFB subunit ( Figure 4A) . These results suggested that p65 might be a more critical regulator of the hypertrophic response, although its function in vivo in accord with NFAT has not been investigated. Standard RelA (p65) gene-targeted mice perish during early embryonic development precluding an analysis of p65's function in the adult heart. 28 To address this limitation, we used a Cre-loxPdependent conditional gene targeting approach to permit specific inactivation of p65 in the heart. Mice homozygous for the p65-loxP-targeted allele (fl/fl) were crossed with Nkx2.5-Cre "knock-in" mice. Western blotting of protein extracts from hearts of 2 month-old p65fl/fl Nkx2.5-Cre mice showed Ͼ80% reduction in p65 protein, which did not change endogenous NFAT protein levels ( Figure 4B ). p65fl/ fl Nkx2.5-Cre mice were generated at predicted mendelian ratios and were overtly normal well into adulthood.
To determine the effect of p65 deletion on NFAT transcriptional activity in the heart in vivo, we crossed p65fl/ fl Nkx2.5-Cre and NFAT-luciferase reporter mice together. 17 As shown in Figure 4C , deletion of p65 significantly reduced NFAT luciferase activity by Ϸ50% compared with wild-type control mice at baseline (sham groups). Remarkably, pressure overload-induced NFAT-luciferase activity after TAC stimulation was also significantly diminished in p65 deleted hearts ( Figure 4C ), consistent with our observation that inhibition of NFB can antagonize calcineurin-NFAT signaling in cardiomyocytes ( Figure 1A ).
Ablation of p65 Reduced Pressure Overload-Induced Cardiac Hypertrophy
Calcineurin-NFAT signaling has been implicated as a central regulator of pathological cardiac hypertrophy, 12 and deletion of NFATc3 or NFATc2 each reduced the hypertrophic response in gene-targeted mice. 29, 30 Based on our observations that ablation of p65 antagonized calcineurin-NFAT signaling, we hypothesized that p65 is also required for efficient cardiac hypertrophy in response to pressure overload stimulation in vivo. Indeed, TAC stimulation for 4 weeks in p65fl/fl Nkx2.5-Cre mice showed reduced cardiac hypertrophy (whole organ and cellular) and fibrosis compared with p65fl/fl and Nkx2.5-Cre control mice ( Figure 5A and Online Figure III, A through D) . Measurement of lung weight normalized to body weight also showed reduced pulmonary congestion in p65fl/fl Nkx2.5-Cre mice after 4 weeks of TAC compared with controls ( Figure 5B ). Echocardiographic assessment of ventricular chamber dimensions and fractional shortening also showed preserved cardiac function and less dilation after TAC in p65fl/fl Nkx2.5-Cre mice compared with controls ( Figure 5C, 5D, and 5E ). Taken together, these results indicate that p65 ablation reduces pressure overloadinduced cardiac hypertrophy and ventricular remodeling, consistent with less hypertrophy and remodeling observed previously in NFATc3-or NFATc2-deleted mice, supporting the hypothesis that these 2 pathways functionally intersect in the heart.
Discussion
We demonstrated for the first time the interdependence between NFAT and NFB signaling in mediating hypertrophic gene expression in the heart. Indeed, hypertrophic agonist-induced NFAT transcriptional activity was partially blocked by inhibition of NFB with the IB supersuppressor, dominant negative IKK␤, or genetic deletion of p65. This result suggests that full transcriptional activation of NFAT requires intact NFB signaling and p65 transcriptional activ- ity. Antithetically, genetic inhibition of calcineurin-NFAT showed compromised NFB transcriptional activation in cardiac myocytes. Consistent with these observations, the potent NFB inhibitor, PDTC, promoted rapid nuclear export of NFAT from the nucleus of stimulated cells leading to reduced NFAT transcriptional activity, although the mechanism underlying this effect was not identified. 31 Mechanistically, we showed that NFAT directly interacts with p65 to form a complex that promotes transcriptional synergy. Cooperative interactions between NFB and other transcription factors have been suggested in the regulation of gene expression. For instance, interactions between NFB and the signal transducer and activator of transcription (STAT) factors are the basis for synergistic transcriptional activation of genes after TNF␣ and interferon-␥ costimulation. 32 Other transcription factors that interact with NFB include AP-1, CREB, NF-IL, myc, and IRF-1. 6 Unlike canonical Rel-containing factors, which often homodimerize on target promoters, NFAT factors share an imperfect Rel homology domain that is only capable of weak DNA binding in the monomeric or dimeric state. To strengthen DNA interaction on target promoters, NFAT factors prefer to interact with other nuclear transcription factors such as AP-1, GATA-4, MEF-2, and now p65-NFB. 14 Under basal conditions, NFAT transcription factors are excluded from the nucleus by phosphorylation of the N-terminal regulatory domain. NFAT transcription factors are prototypical effectors of calcineurin signaling. 33 Calcineurin directly interacts with NFAT through a conserved docking motif, and on activation by calcium/calmodulin, calcineurin dephosphorylates NFAT, unmasking a nuclear localization signal. NFAT subsequently enters the nucleus and activates gene transcription. 33 Our data indicate that intracellular shuttling of NFAT is regulated by NFB signaling, in part, by direct binding of the transcription factors themselves. Thus, direct interaction between NFAT and NFB provides a new regulatory mechanism for NFAT transcriptional activation by affecting the nuclear import and export equilibrium of each factor. NFB nuclear translocation induced by IKK␤ or p65-RHD enhances NFAT nuclear localization. However, basal calcineurin activity is required for IKK␤or p65-RHDinduced NFAT nuclear retention since this effect was blocked by the calcineurin inhibitory protein Cain. Thus, some level of calcineurin-mediated basal dephosphorylation of NFAT is necessary for NFAT to periodically transit through the nucleus to have the opportunity to bind p65-NFB and be retained.
NFB plays important roles in cardiac hypertrophy and remodeling. For example, in vitro studies have shown that NFB is required for hypertrophic growth of cardiomyocytes in response to GPCR agonists such as phenylephrine, endothelin-1 and angiotensin II. 26, 34, 35 In addition, in vivo studies using different animal models of NFB inactivation by IB␣M mutant overexpression, p65 silencing, or p50 deletion also showed reduced cardiac hypertrophy in response to aortic banding, 36 chronic infusion of GPCR agonists, 37, 38 and transgenic overexpression of myotrophin. 39, 40 However, Inhibition of NFB signaling in cardiac-specific IKK␤ or NEMO knockout mice showed enhanced hypertrophy and pathological remodeling. 41, 42 Thus manipulation of different components of the NFB signaling pathway may have distinct functional consequences in the heart.
Intriguingly, we observed upregulation of p65 but not p50 in the heart after pressure overload. In addition, we were not able to detect association of p50 with NFAT by immunoprecipitation in cardiomyocytes (data not shown). These results suggest that different NFB subunits may have distinct roles in signal transduction and cellular function. Indeed, p65 nuclear translocation and cytokine expression were observed in p50-deficient cardiomyocytes on stimulation, suggesting that p65 functions independent of p50. 43 In addition, embryonic fibroblasts from p65 null mice were deficient in activating certain TNF␣-inducible genes with NFB binding sites, 44 whereas p50 null cells showed normal activation. 45 Our results also provide new insights into how NFB induces cardiac hypertrophy and fetal gene expression. No NFB binding sites have been identified in the promoter regions of adult or fetal cardiac genes associated with cardiac hypertrophy. We showed that NFB affected cardiac hypertrophy and remodeling through a physical interaction with the well-defined hypertrophic transcription factor NFAT, for which many direct promoter interaction sites have been identified in hypertrophic genes. 12, 30 Indeed, overexpression of a constitutively activated NFAT mutant protein resulted in cardiac hypertrophy in transgenic mice, suggesting that NFAT activation is sufficient to promote the hypertrophic response of the heart. 12 In addition, genetic inhibition of NFAT isoforms attenuated the hypertrophic response to hypertrophic agonists and pressure overload. 29, 30, 46 Blocking of NFB activity could represent a novel approach to attenuate cardiac hypertrophy and adverse remodeling. We demonstrated that p65 ablation reduced pressure overload-induced cardiac hypertrophy with preserved cardiac function, possibly through diminished NFAT signaling. In addition, cardiac deletion of p65 also showed reduced cardiac hypertrophy and ventricular remodeling with improved contractile function in response to myocardial infarction (data not shown), and similar effects were observed in a transgenic mouse expressing IB supersuppressor. 47 Great efforts have been made for the development of highly specific NFB inhibitors for treating autoimmune diseases and different types of cancer, some of which are being evaluated in phase II clinical trials. Although the calcineurin inhibitors cyclosporine A and FK506 dramatically attenuate cardiac hypertrophy in most animal models, 48 severe side effects preclude their use for heart disease in humans. 49 -51 Thus, targeting NFB may represent a valid alternative therapeutic strategy in treating hypertrophy or heart failure, which secondarily would reduce the effectiveness of NFAT activity in the heart. 
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